Choosing wisely in the era of biologics for asthma

In the era of biologics for asthma, clinicians, researchers, and guideline developers face an increasingly important challenge. In addition to critically appraising the evidence for efficacy of novel therapies for specific asthma phenotypes, we must consider the real-life cost and effectiveness of increasingly personalized medicine. Put simply, we must consider health economics and prescribe wisely.

https://ift.tt/2Gvbfi0